Riyadh, Saudi Arabia — QOMEL H1 profits rose 7.6% year-on-year to SAR 11.84 million in the first half of 2025, supported by stronger sales and better operations.
QOMEL H1 Profits Rise 7.6% to SAR 11.84M on Sales and Ops Growth
QOMEL, a Riyadh-based pharmaceutical and medical supplies firm, posted a net profit of SAR 11.84 million in H1 2025. This marked a 7.64% rise from SAR 11 million in H1 2024. Revenue jumped 21.6% to SAR 71.23 million, fueled by growing demand for registered pharmaceuticals and new product additions.
What Drove Profitability
- Revenue growth: Sales rose due to product registration expansion and deeper market reach.
- Improved operations: Better logistics performance and stronger sales from existing and new products helped boost profit.
Strategic Highlights
- Pipeline progress: QOMEL recently raised capital and secured an $8.26 million NUPCO contract, which supports its growth plans.
- Manufacturing expansion: A new pharmaceutical plant is set to begin operations by late 2025, which may further improve margins.
Investor Takeaways
- Stable growth: Solid revenue gains and moderate profit increase reflect effective business scaling.
- Balanced approach: The company blends organic growth with new product development to sustain momentum.
- Future upside: Commissioning the plant could become a long-term earnings driver.
Key Watchpoints
- Plant timeline: The pace of construction and mix of outputs will directly affect margins.
- Product approvals: Timely clearance of high-demand drugs remains crucial.
- Competitive pressures: Price discipline will be essential as the product range grows.
THE SAUDI STANDARD’S VIEW: QOMEL’s Steady Profit Rise Reflects Pharma Sector’s Resilience and Product Strategy Execution
QOMEL’s 7.6% profit increase and 21.6% revenue surge in H1 2025 highlight the strength of Saudi Arabia’s pharmaceutical sector. These results reflect smart operational moves and timely expansion of product lines—key signs of maturity in the local health industry.
- Market-led growth: Higher sales from new and existing drugs show that QOMEL effectively meets local health needs while expanding regionally.
- Operational discipline: Efficiency in supply chains and production helped raise profit without raising costs, proving QOMEL’s readiness to manage larger operations.
- Vision 2030 alignment: QOMEL’s growth fits into the Health Sector Transformation Program, which promotes local manufacturing and secure medical supplies.
- Attractive to investors: As medical product demand grows, QOMEL’s consistent performance supports investor interest in Saudi-listed healthcare and medtech firms.
In conclusion, QOMEL H1 profits reflect a broader rise in Saudi Arabia’s pharmaceutical capacity. With localization efforts growing, the company is well-positioned to lead in public health delivery and economic diversification.
Related Reading
• Explore QOMEL’s growth and the Saudi pharmaceutical sector
• Browse the latest Saudi earnings reports and listed company updates
